Drugs / Allogeneic γδT cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03575299 | Jun 2018 → Jun 2021 | multidrug-resistant tuberculosis | Zhinan Yin, Ph.D. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04765462 | Mar 2021 → Dec 2023 | cancer | Chinese PLA General Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic γδ T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04765462 ↗ |
| Modality | Cell therapy | “Here, we proposed an allogeneic Vγ9Vδ2 T-cell-based immunotherapy strategy and clinically evaluated its safety and efficacy in patients with multidrug-resistant TB (MDR-TB).” PMID 34975844 ↗ Dec 2021 |
| Route | Intravenous | “Allogeneic γδT cells from healthy donor will be administrated intravenously to patients with the MDR-TB” NCT03575299 ↗ |